866-997-4948(US-Canada Toll Free)

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 45 Pages

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016, provides an overview of the Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) pipeline landscape.

MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Predisposing factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA may be managed by the use of antibiotics and by maintaining hygienic conditions.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 4 respectively.Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections.

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections Overview 6
Therapeutics Development 7
Pipeline Products for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Overview 7
Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Therapeutics under Development by Companies 8
Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Products under Development by Companies 11
Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Companies Involved in Therapeutics Development 12
Allergan Plc 12
Galapagos NV 13
Merck & Co Inc 14
Syntiron LLC 15
Valevia UK Ltd 16
Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
acorafloxacin hydrochloride - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
GLPG-1492 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
solithromycin - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Staphylococcus aureus vaccine - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
VAL-301 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Dormant Projects 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45

List of Tables
Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Allergan Plc, H2 2016 12
Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Galapagos NV, H2 2016 13
Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Merck & Co Inc, H2 2016 14
Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Syntiron LLC, H2 2016 15
Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Valevia UK Ltd, H2 2016 16
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Stage and Target, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 25
Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Dormant Projects, H2 2016 43

List of Figures
Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Targets, H2 2016 18
Number of Products by Stage and Targets, H2 2016 18
Number of Products by Mechanism of Actions, H2 2016 20
Number of Products by Stage and Mechanism of Actions, H2 2016 20
Number of Products by Routes of Administration, H2 2016 22
Number of Products by Stage and Routes of Administration, H2 2016 22
Number of Products by Molecule Types, H2 2016 24
Number of Products by Stage and Molecule Types, H2 2016 24

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *